Trials / Completed
CompletedNCT02776813
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Cogent Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ACTR087 | |
| BIOLOGICAL | rituximab |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2020-02-12
- Completion
- 2020-02-12
- First posted
- 2016-05-18
- Last updated
- 2020-03-31
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02776813. Inclusion in this directory is not an endorsement.